7
Participants
Start Date
April 30, 2007
Primary Completion Date
February 28, 2009
Study Completion Date
February 28, 2009
Bortezomib
Bortezomib will be administered at 1.3 mglm2 IVP on Days 1. 4, 8, and 11. Response will be assessed subsequent to each cycle. A total of 8 cycles would beplanned. Patients would be removed subsequent to Cycle 2. if progression of disease is documented.
The Cancer Center at Hackensack University Medical Center, Hackensack
Collaborators (1)
Genentech, Inc.
INDUSTRY
Hackensack Meridian Health
OTHER